home2018-11-09T09:52:34+00:00

ULTRASOUND
CIRCULATION MONITORING

ULTRASOUND
CIRCULATION MONITORING

Continuous blood flow monitoring for early detection and diagnosis.

Cimon Medical is based on groundbreaking, patented technology originating from the internationally renowned ultrasound environment at NTNU and St. Olavs Hospital.

Our vision is to develop products for a wide range of clinical applications related to continuous monitoring of blood flow within: newborn intensive care, peripheral arterial disease and sepsis diagnosis.

Continuous blood flow monitoring for early detection and diagnosis.

Cimon Medical is based on groundbreaking, patented technology originating from the internationally renowned ultrasound environment at NTNU and St. Olavs Hospital.

Our vision is to develop products for a wide range of clinical applications related to continuous monitoring of blood flow within: newborn intensive care, peripheral arterial disease and sepsis diagnosis.

Technology applications

Neonatal monitoring

The need

1 in 10 children are born prematurely each year. Preterm children have large fluctuations in cerebral blood flow, increasing the risk of brain damage substantially. Premature birth increases the risk of brain damage. Currently there exists no direct continuous measurement of cerebral blood flow.

The solution

Using a new non-invasive ultrasound probe and application specific signal analysis, our technology measures and detects changes in cerebral blood flow in real-time. This allows clinicians to act early to prevent brain damage by timing medical interventions. The technology is operator independent and does not require ultrasound expertise.

Clinical activity

A feasibility study with 23 neonates born at different gestational ages was completed during spring 2018. The study indicated that the CIMON Medical technology provides reliable and continuous cerebral blood flow data of high quality. As of autumn 2018, four further studies is being initiated at St. Olav’s Hospital, Oslo University Hospital (Rikshospitalet), and The Hospital for Sick Children in Canada.

Sepsis diagnosis

The need

Sepsis is a bacterial infection with high mortality. Globally, 120 million people develop severe infections each year. In 30 million of these cases, the infection progresses to sepsis. 30 % of these patients eventually die of the infection. Accurately sepsis diagnosis at an early stage is critical as the risk of death increases with every passing hour the condition goes untreated. Despite this, there are currently no diagnostic tools for early detection of sepsis.

The solution

Changes in micro circulation is an early indicator of sepsis development. Using a new, non-invasive, ultrasound probe and application specific signal analysis, our technology enables early detection of sepsis through continuous monitoring of microcirculation. This enables early medical intervention with antibiotics. The technology is operator independent and does not require ultrasound expertise.

Clinical activity

A feasibility study with 4 patients was completed during spring 2018. The study verified the CIMON Medical technology against established methods. Two further are initiated at St. Olav’s Hospital.

Diabetes monitoring

The need

Peripheral arterial disease (PAD) is a disease leading to tissue damage, foot ulcers, and amputation. The disease is caused by occlusion of the arteries and is commonly treated with surgery to remove occlusions. In 2010, 202 million people around the world were living with PAD. Currently, there is no simple, user-independent tool for detection of initial occlusion in the arteries, nor tools for detecting complications after surgery.

The solution

Using a new non-invasive ultrasound probe and application specific signal analysis, our technology enables both early diagnosis of PAD as well as complication detection after surgery. The technology can also be used as a tool for decision support during surgical treatment of PAD. The technology is operator independent and does not require ultrasound expertise.

Clinical activity

A feasibility study with 10 patients was completed during the spring of 2017. The study verified the CIMON Medical technology against established methods. Three further studies are initiated at St. Olav’s Hospital, Oslo University Hospital, and Hospital of Southern Norway.

Technology applications

Neonatal monitoring

The need

1 in 10 children are born prematurely each year. Preterm children have large fluctuations in cerebral blood flow, increasing the risk of brain damage substantially. Premature birth increases the risk of brain damage. Currently there exists no direct continuous measurement of cerebral blood flow.

The solution

Using a new non-invasive ultrasound probe and application specific signal analysis, our technology measures and detects changes in cerebral blood flow in real-time. This allows clinicians to act early to prevent brain damage by timing medical interventions. The technology is operator independent and does not require ultrasound expertise.

Clinical activity

A feasibility study with 23 neonates born at different gestational ages was completed during spring 2018. The study indicated that the CIMON Medical technology provides reliable and continuous cerebral blood flow data of high quality. As of autumn 2018, four further studies is being initiated at St. Olav’s Hospital, Oslo University Hospital (Rikshospitalet), and The Hospital for Sick Children in Canada.

Sepsis diagnosis

The need

Sepsis is a bacterial infection with high mortality. Globally, 120 million people develop severe infections each year. In 30 million of these cases, the infection progresses to sepsis. 30 % of these patients eventually die of the infection. Accurately sepsis diagnosis at an early stage is critical as the risk of death increases with every passing hour the condition goes untreated. Despite this, there are currently no diagnostic tools for early detection of sepsis.

The solution

Changes in micro circulation is an early indicator of sepsis development. Using a new, non-invasive, ultrasound probe and application specific signal analysis, our technology enables early detection of sepsis through continuous monitoring of microcirculation. This enables early medical intervention with antibiotics. The technology is operator independent and does not require ultrasound expertise.

Clinical activity

A feasibility study with 4 patients was completed during spring 2018. The study verified the CIMON Medical technology against established methods. Two further are initiated at St. Olav’s Hospital.

Diabetes monitoring

The need

Peripheral arterial disease (PAD) is a disease leading to tissue damage, foot ulcers, and amputation. The disease is caused by occlusion of the arteries and is commonly treated with surgery to remove occlusions. In 2010, 202 million people around the world were living with PAD. Currently, there is no simple, user-independent tool for detection of initial occlusion in the arteries, nor tools for detecting complications after surgery.

The solution

Using a new non-invasive ultrasound probe and application specific signal analysis, our technology enables both early diagnosis of PAD as well as complication detection after surgery. The technology can also be used as a tool for decision support during surgical treatment of PAD. The technology is operator independent and does not require ultrasound expertise.

Clinical activity

A feasibility study with 10 patients was completed during the spring of 2017. The study verified the CIMON Medical technology against established methods. Three further studies are initiated at St. Olav’s Hospital, Oslo University Hospital, and Hospital of Southern Norway.

History

CIMON Medical is founded based on technology from the Department of Circulation and Medical Imaging (ISB) at the Norwegian University of Science and Technology (NTNU). This particular technology is invented by Professor Hans Torp, a driving force in the Trondheim ultrasound community.

In Trondheim and at ISB, innovation in ultrasound goes back a long time. Already in the early 70’s the department developed the first instrument that could non-invasively measure blood flow in the aorta, replacing catheter-based measurements of pressure drops in heart valve stenosis.

The innovation was picked up by Vingmed, and by 1986 spun out into Vingmed Sound. Since then, Trondheim and NTNU has been at the forefront of ultrasound innovation, developing Doppler ultrasound with color in the 1980’s and in vivo 3D embryo imaging in the 1990’s. After GE’s acquisition of Vingmed in 1998, the Trondheim environment has continued innovating, creating the world’s first commercially available handheld ultrasound device in 2009.

Presently, CIMON Medical is industrializing ultrasound innovations from Trondheim, allowing for the first time continuous monitoring of blood flow for a variety of applications.

Team

Christian Gutvik, PhD
Christian Gutvik, PhDInterim CEO
Christian is PhD in Medical Technology from NTNU, and has 14 years of experience from applied research, entrepreneurship, business development, and technology management. He was the R&D manager of Aptomar, a company that went from delivering the first prototype in 2008 to reaching a revenue of 86 million NOK in 2012 and reached 19th place of Deloitte’s Technology FAST 500 EMEA, ranking 2nd in Norway. After Aptomar, Christian joined NTNU technology Transfer, where he has been involved in a number of spin-outs, as the lead project manager and as a board member. In Cimon Medical, Christian brings a solid business and technology background together, enabling us to create tomorrow’s ultrasound products.
Prof. Hans Torp
Prof. Hans TorpInventor
Professor Torp is a world leading scientist specializing in medical ultrasound technology, Doppler blood flow imaging, wave propagation and beam forming. He is the Head of the ultrasound research group at ISB, NTNU, a member of the technical program committee for the IEEE International Ultrasonic Symposium, and an associate editor of IEEE Transactions on Ultrasonics, Ferroelectricity and Frequency control. With over 40 patent applications under his belt, he is a prolific inventor, having bridged the gap between research and industry for over 30 years. Professor Torp is the primary inventor of Cimon Medical’s technology, and further infuses the company with a solid research background together with a life-long commitment to innovation and industrialization, enabling us to create tomorrow’s ultrasound products.

St.Olavs Hospital collaborates closely with NTNU on education and has a special responsibility for sharing knowledge and supporting professional development in the specialist health services in central Norway.

The regional hospital is responsible for the most specialized treatment services, and therefore has patients throughout central Norway. St. Olavs Hospital also has some national functions and collaborates with other university hospitals.

NTNU Technology Transfer AS works to create value from research based ideas that come out of The Norwegian University of Science and Technology (NTNU) and The Central Norway Regional Health Authority (Helse Midt-Norge).

NTNU Technology Transfers  goal is  to create benefit to society from these ideas in the form of new products, new services, new industries and new jobs.

NTNU is Norway’s university for higher education in technology and natural sciences.

NTNU has 9 faculties and 55 institutes and more than 100 laboratories. The university employs approximately 5360 academic staff and has 40 000 students.

The university is recognized for a broad cooperation with national and international businesses and has an annual budget of approx. 9 billion Norwegian kroner.

Email: contact@cimonmedical.com
Phone: +47 920 87 545

Email: contact@cimonmedical.com
Phone: +47 920 87 545